Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL66271 | 0.89 | TAAR1 (0.57) | TAAR1SLC6A3DRD2SLC6A4DAO | |
| SCHEMBL27745167 | 0.81 | TAAR1 (0.53) | TAAR1SLC6A3DRD2SLC6A4DAO | |
| SCHEMBL11516858 | 0.81 | TAAR1 (0.53) | TAAR1SLC6A3DRD2SLC6A4DAO | |
| SCHEMBL29018933 | 0.81 | TAAR1 (0.53) | TAAR1SLC6A3DRD2SLC6A4IDO1 | |
| SCHEMBL30462204 | 0.81 | TAAR1 (0.53) | TAAR1SLC6A3DRD2SLC6A4IDO1 | |
| SCHEMBL1047725 | 0.79 | TAAR1 (0.59) | TAAR1SLC6A3DRD2SLC6A4DAO | |
| SCHEMBL167999 | 0.78 | TAAR1 (0.52) | TAAR1SLC6A3DAOIDO1AGXT | |
| SCHEMBL9714684 | 0.78 | DRD2 (0.53) | TAAR1DRD2 | |
| SCHEMBL6083781 | 0.78 | TAAR1 (0.53) | TAAR1DAOIDO1MAOAMAOB | |
| SCHEMBL22320003 | 0.78 | TSHR (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088837-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC | 2012-04-12 | — | — | US | disclosed |
| US-7981923-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100130742-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | HARRIS III RALPH NEW | 2010-05-27 | — | — | US | disclosed |
| US-7576103-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-08-18 | — | — | US | disclosed |
| US-7473690-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-01-06 | — | — | US | disclosed |
| EP-0194764-B1 | PESTICIDAL COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-07-12 | — | — | EP | disclosed |
| EP-0194764-A1 | Pesticidal compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-09-17 | — | — | EP | disclosed |
| US-4415572-A | CARDIOTONIC AND INOTROPIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130742-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | INSRR, TTN, INSR | TAAR1 105/4885SLC6A3 2816/4885DRD2 1179/4885 |
| US-20120088837-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | INSRR, RIF1, TTR | TAAR1 166/4885SLC6A3 3778/4885DRD2 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.